Experience A Better Depression Treatment That Is Drug-Free, Non-Invasive & FDA Approved
Living with major depressive disorder (MDD) is like trying to run with 50-pound sandbags tied to your ankles. Living? Nope, suffering from depression takes the concept of living to something more appropriately called “barely existing.”
For the 14 million adults who are affected with depression each year, including 3 million individuals with MDD, life becomes shrouded in the muted tones of gray to black. Not only does daily existence feel rooted in despair and hopelessness, but in addition, all sorts of peripheral damage is done as a result of this serious mental health disorder. Disordered eating habits can emerge, from poor nutrition to a full-blown eating disorder. Self-destructive behaviors—including self-harm and substance abuse—can add fuel to the fire, further incapacitating one’s quality of life.
While antidepressants and psychotherapy may offer relief to some, many remain mired in the MDD mud. Finding depression solutions has proved difficult and treating patients with antidepressants can be tricky, leaving some doctors to rely on trial and error methods in hopes of landing the right medication fit. For roughly 50% of patients managing depression, not only is there no relief from the symptoms, but nasty side effects—weight gain, insomnia, headaches, nausea, and sexual dysfunction—are what the patient experiences.
For depression patients who are medication-resistant there is newfound hope in the promising results seen with TMS. TMS trial results over the past decade have repeatedly underscored its efficacy in safely treating major depression, with statistically significant improvements in symptoms, and without anesthesia. As news of the high success rate of TMS therapy spreads, more people are seeking this alternative depression treatment option out.
One such multicenter clinical trial spanned 16 weeks and enrolled 230 subjects with drug-resistant MDD. The study took place in 22 medical centers located in the U.S., Europe, Canada, and Israel and sought to evaluate the efficacy and safety of TMS in its subjects. This double-blind placebo-controlled study demonstrated a significant reduction in the MDD symptoms, with 32.6% experiencing remission and 38.4% experiencing reduction in symptoms.
Another study out of Rush University Medical Center in Chicago, Illinois involved 301 depression patients who were randomly assigned to receive either TMS treatment or a sham therapy over a six-week period. Again, the results confirmed a positive treatment result for a majority of the patients, with a low relapse rate. Study principal investigator, Philip G. Janicak, M.D., a professor of psychiatry at Rush University, stated, “The results of the follow-up study further support TMS as a viable treatment option for patients with major depression who have not responded to conventional antidepressant medications.” Janicak continues, “After acute response to TMS, a standardized regimen of antidepressant medication maintained the acute benefit in the majority of patients over a six-month period.”